Autologous Stem Cell Transplantation in Myelodysplastic Syndromes

Witte, Théo de; Suciu, Stefan; Brand, Ronald; Muus, Petra

doi:10.1053/j.seminhematol.2007.08.006

Cited by 12 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, consistent with our study, CD38 expression from the CD34+ cells could serve as a novel target for MDS . Moreover, stem cells are beneficial in the recovery of hematopoiesis, whereas stem cell phenotypes were found more frequently among precursor cells from patients suffering from MDS . Similarly, the number of plasma cells was upregulated among MDS patients, suggesting that more viable cells are observed in patients suffering from MDS .…”

Section: Discussionsupporting

confidence: 89%

“…27 Moreover, stem cells are beneficial in the recovery of hematopoiesis, whereas stem cell phenotypes were found more frequently among precursor cells from patients suffering from MDS. 28,29 Similarly, the number of plasma cells was upregulated among MDS patients, suggesting that more viable cells are observed in patients suffering from MDS. 30 Moreover, a previous study had validated that suppressing MAPK could inhibit the differentiation of bone marrow stromal cells in a way that could upregulate expression as well as phosphorylation of both ERK and JNK.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Retracted: EBF1 gene promotes the proliferation and inhibits the apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome through negative regulation of mitogen‐activated protein kinase axis

Hou

Hao²,

Wang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

The transcription factor, early B cell factor 1 (EBF1), plays a vital role in the lineage specification involving early B cell development and the onset of myelodysplastic syndrome (MDS). Therefore, to investigate whether or not EBF1 affects MDS as well as the transcription factor's underlying mechanism, we used CD34+ hematopoietic stem cells in bone marrow from patients with MDS. The extracted cells were then transfected with a series of EBF1, short hairpin RNA against EBF1 (shEBF1), and SB203580 (a specific mitogen‐activated protein kinase [MAPK] axis inhibitor). The effects EBF1 gene and MAPK axis had on cell proliferation, apoptosis, and migration were determined by in vitro cell culturing. We made observations that involved EBF1 inhibiting the messenger RNA (mRNA) level of p38 MAPK, increasing the mRNA levels of extracellular‐signal–regulated kinase (ERK), c‐Jun N‐terminal kinase (JNK), extracellular‐signal–regulated kinase 5 (ERK5), decreasing the protein expression of Bcl‐2–associated X protein (Bax), and finally elevating the protein levels of B cell lymphoma/leukemia‐2 (Bcl‐2), stem cell factor (SCF), erythropoietin receptor (EpoR), p‐ERK, p‐JNK, p‐ERK5, cyclin D, cyclin E, cyclin‐dependent kinase 2 (CDK2), and CDK6, implying that EBF1 may very well have an inhibitory role in the MAPK axis. Another discovery found that EBF1 had a positive effect on the promotion of bone marrow CD34+ cell proliferation as well as its migration, but inhibited the apoptosis of cells. The results we obtained from this study indicated that the EBF1 gene suppresses the activation of the MAPK axis, thereby promoting both the proliferation and migration of bone marrow CD34+ cells as well as inhibiting the associating apoptosis. The effects of the EBF1 gene are likely to present a new therapeutic target in preventing the progression of MDS.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Retracted: EBF1 gene promotes the proliferation and inhibits the apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome through negative regulation of mitogen‐activated protein kinase axis

Hou

Hao²,

Wang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Allogeneic HCT can cure or improve outcome in a wide variety of diseases, including leukemia, lymphoma, myeloproliferative disorders, myelodysplastic syndrome (MDS), bone marrow (BM) failure syndromes, congenital immunodeficiencies, enzyme deficiencies, and hemoglobinopathies [13][14][15][16][17]. However, because allogeneic HCT is associated with significant morbidity and mortality because of regimen-related toxicity (RRT) [18], infection [19], and graft versus host disease (GVHD) [20], a recommendation regarding transplantation for the individual patient requires careful risk assessment that takes into account disease status [21], comorbidities, previous therapies, other standard therapies available for the underlying disease [22], donor stem cell source [23], and histoincompatibility [24].…”

Section: Background To Hct Including Posttransplant Immune Recoverymentioning

confidence: 99%

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

Tomblyn¹,

Chiller²,

Einsele³

et al. 2009

Biology of Blood and Marrow Transplantation

1,573

1,540

View full text Add to dashboard Cite

“…Since a more intensive consolidation treatment was necessary, we tried through adopting auto-HSCT. After the surgery, the patient had slow hematopoietic recovery which related with the patient’s age and history of MDS [8, 9]. …”

Section: Discussionmentioning

confidence: 99%

Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report

Wang

et al. 2014

Cell Biochem Biophys

View full text Add to dashboard Cite

The treatment for AML (Acute myeloid/myelogenous leukemia) transformed from MDS (myelodysplastic syndrome) is difficult and controversial clinically, especially in elder patients. In this case report, we diagnosed a 59-year-old female patient with AML-M2a transformed form MDS which might be caused by her chemotherapy for mastocarcinoma. After achieving complete remission (CR) through combined chemotherapy, autologous peripheral blood stem cell transplantation (auto-PBSCT) was attempted. Following auto-HSCT, marrow showed continuous CR but the patient later developed extramedullary bone-infiltration relapse. Then local radiotherapy has been applied, and the patient now has prolonged survival. This is the first (or a successful) case report of auto-HSCT in an elderly patient with AML transformed from MDS.

show abstract

Autologous Stem Cell Transplantation in Myelodysplastic Syndromes

Cited by 12 publications

References 24 publications

Retracted: EBF1 gene promotes the proliferation and inhibits the apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome through negative regulation of mitogen‐activated protein kinase axis

Retracted: EBF1 gene promotes the proliferation and inhibits the apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome through negative regulation of mitogen‐activated protein kinase axis

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report

Contact Info

Product

Resources

About